Michael Latham - IShares Pharmaceuticals President Trustee
| IHE Etf | USD 65.91 0.55 0.84% |
Mr. Michael A. Latham serves as President, Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund. He was a Trustee of the Trust since 2010 and President of the Trust since 2007. Mr. Latham served as Principal Financial Officer of the Trust from 2002 until 2007. Mr. Latham has served as a Director of iShares, Inc. since 2010, President of iShares, Inc. since 2007, Principal Financial Officer of iShares, Inc. from 2002 until 2007, a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010 and President of iShares MSCI Russia Capped Index Fund, Inc. since 2010. Mr. Latham is the global head of BlackRocks iShares exchangetraded fund business. In addition, he has over 15 years of experience as part of BlackRock, Inc. and BlackRocks predecessor entities. Prior to assuming his current responsibilities in April 2009 and July 2010, he was head of BlackRocks iShares exchangetraded fund business for the U.S. and Canada and Chief Operating Officer for the U.S. iShares business. He previously held a variety of operating positions within the firm
| Age | 53 |
| Tenure | 15 years |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 610.64 Million |
| Average Trading Valume | 79,088 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Found 10 records | One Year Return | ||
| Amy Schioldager | iShares Healthcare ETF | 57 | |
| Michael Riley | SPDR SP Pharmaceuticals | 43 | |
| Matt Tucker | iShares Healthcare ETF | N/A | |
| Ira Shapiro | iShares Insurance ETF | 51 | |
| Ira Shapiro | iShares Healthcare ETF | 51 | |
| Geoffrey Flynn | iShares Healthcare ETF | N/A | |
| Matt Tucker | iShares Insurance ETF | N/A | |
| Geoffrey Flynn | iShares Insurance ETF | N/A | |
| James Ross | SPDR SP Pharmaceuticals | 51 | |
| Amy Schioldager | iShares Insurance ETF | 55 | |
iShares Pharmaceuticals Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.59 | |||
| Total Asset | 381.08 M | |||
| One Year Return | 6.50 % | |||
| Three Year Return | 1.60 % | |||
| Five Year Return | 6.10 % | |||
| Ten Year Return | 4.20 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.